Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass

Journal of Extra-Corporeal Technology

Volumn 33, Issue 2, 2001, Pages 117-125

  Fabrizio, M Charlene ^a,b  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cardiopulmonary bypass; Ecarin clotting time; Heparin induced thrombocytopenia; Hirudin; Lepirudin; Thrombolastograph

Indexed keywords

ANCROD; ARGATROBAN; DANAPAROID; ECARIN; ENOXAPARIN; HEPARIN; HIRUDIN; LEPIRUDIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; DRUG INDUCED DISEASE; HEMODYNAMIC MONITORING; HEPARINIZATION; HUMAN; PATIENT MONITORING; THROMBOCYTOPENIA;

EID: 0034998175     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Brieger DB, Mak KH, Marchant, KK, et al. Heparin-induced thrombocytopenia: A review. J Am Coll Cardiol. 1998;3:1449-59.
2. Warkentin, TE. Recent advancements in the management of heparin-induced thrombocytopenia. ThromboSite Newslett. 1998;1:4-6.
3. Koster A, Kuppe H, Crystal G, et al. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin. Anesth Analg. 2000;90:292-8.
4. Blakeman B. Management of heparin-induced thrombocytopenia: A cardiovascular surgeon's perspective. Semin Hematol. 1999; 36(Suppl.):22-28.
5. Walls JT, Curtis JJ, Silver D, et al. Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery. 1990; 108:686-93.
6. Warkentin TE. Heparin-induced thrombcytopenia and its treatment. J Thromb. 2000;9:S29-35.
7. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost. 1992;68:95-6.
8. Greinacher A, Potzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF-4 heparin complex as the major antigen. Thromb Haemost. 1994;71:247-51.
9. Warkentin TE. Heparin-induced trombocytopenia: A ten-year retrospective. Ann Rev Med. 1999;50:129-47.
10. Warkentin TE, Chong BH, Gremacher A. Heparin-induced thrombocstopenia: Towards consensus. Thromb Haemost 1998;79:1-7.
11. Aster RH. Heparin-induced thrombocytopenia and thrombosis (editorial). N Engl J Med 1995;332:1374-76.
12. Towne JB, Bernhard VM, Hussey C, et al. White clot syndrome. Arch Surg. 1979, 114:372-7.
13. Nand S, Wong W, Yuen B, et al Clinical risk factors associated with the development of thrombosis in patients with HIT AM J Hematol. 1997;56:12-6.
14. Castel SM, D'Attellis N, Carpentier A Use of low-molecular-weight heparin in cardiac surgery In. New Anticoagulants for the Cardiovascular Patient. Pifarre R, ed. Philadelphia. Hanley & Belfus, 1997: 137-44.
15. Markwardt F The development of hirudin as an antithrombin drug. In: New Anticoagulants for the Cardiovascular Patient.Pifarre R, ed. Philadelphia: Hanley & Belfus, 1997:143-60.
16. Walenga JM, Pitarre R. Hirudin as an Anticoagulant in Cardiopulmonary Bypass In: New Anticoagulants for the Cardiovascular Patient. Pifarre R, ed. Philadelphia: Hanley & Belfus; 1997:175-86.
17. Reiss FC, Poetzsch B, Mueller-Berghaus G. Recombinant hirudin as an anticoagulant during cardiac surgery. In: New Anticoagulants for the Cardiovascular Patient. Pifarre R, ed. Philadelphia: Hanley & Belfus; 1997:197-221
18. Lewis BE, Walenga JM, Pifarre R, et al. Argatroban in the management of patients with heparin-induced thrombocytopenia and thrombosis syndrome. In: New Anticoagulants for the Cardiovascular Patient. Pifarre R, ed. Philadelphia Hanley & Belfus; 1997:223-9.
19. Walenga JM, Koza MJ, Lonchyna V, et al. Experimental evaluation of argatroban for cardiopulmonary bypass. In: New Anticoagulants for the Cardiovascular Patient. Pifarre R, ed. Philadelphia: Hanley & Belfus; 1997:251-63.
20. Cole CW. Ancrod as a practical alternative to heparin. In: New Anticoagulants for the Cardiovascular Patient. Pifarre R, ed. Philadelphia: Hanley & Belfus; 1997:423-9.
21. Magnani HN, Beijering RJR, Ten Cate JW, et al. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: New Anticoagulants for the Cardiovascular Patient. Pifarre R, ed. Philadelphia: Hanley & Belfus; 1997: 487-500.
22. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractioned heparin. N Engl J Med. 1995;332:1330-05.
23. Refludan® product literature. Hoechst Marion Roussel. Frankfurt, Germany (now: Aventis Pharma AG, Stasbourg, France).
24. Koster A, Kuppe H, Mertzlufft F. R-hirudin rebound after CPB in patients with HIT (type II) Anes Analg. 1999;88:160S.
25. Ecarin Clotting Time Product Literature. Raleigh, North Carolina: Cardiovascular Diagnostics Inc.
26. Potszch B, Hund S, Madlener K, et al. Monitoring of recombinant hirudin: Assessment of a plasma-based ecarin clotting time assay. Throm Res. 1997;86:373-83.
27. Potzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - Assessment of the whole blood ecarin clotting time. Thromb Haemost. 1997;77:920-5.
28. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-7.
29. Koster A, Kuppe H, Hetzer R, et al. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology. 1998;89:777-80.